Cannabinoid receptor 2 agonist, lenabasum, for the treatment of pulmonary exacerbations in cystic fibrosis
Natalie E. West(Johns Hopkins University), James F. Chmiel(Riley Hospital for Children), Michael W. Konstan(Case Western Reserve University), S. Constantine(Corbus Pharmaceuticals (United States)), Donald R. VanDevanter(Case Western Reserve University), Amalia Magaret(University of Namur), E. Amelina(Federal Medical-Biological Agency), Henry L. Dorkin(Boston Children's Hospital), Sivagurunathan Sutharsan(Ruhrlandklinik), J.S. Elborn(Royal Brompton Hospital), Lena Hjelte(Karolinska University Hospital), D.G. Downey(Queen's University Belfast), Barbara White(Corbus Pharmaceuticals (United States)), Henryk Mazurek(National Center for Tuberculosis and Lung Disease), R. Chiron(Institut Universitaire de Recherche Clinique), Amparó Solé(Hospital Universitari i Politècnic La Fe), Quinn Dinh(Corbus Pharmaceuticals (United States)), Carla Columbo(University of Milan), Elizabeth Tullis(St. Michael's Hospital), Nancy Dgetluck(Corbus Pharmaceuticals (United States)), István Laki(Semmelweis University), Patrick A. Flume(Medical University of South Carolina)
Cited by 5
Related Papers
Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del<i>CFTR</i>
|New England Journal of Medicine|2015|1.6k
Randomized Trial of Omalizumab (Anti-IgE) for Asthma in Inner-City Children
|New England Journal of Medicine|2011|870
Effect of VX-770 in Persons with Cystic Fibrosis and the G551D- <i>CFTR</i> Mutation
|New England Journal of Medicine|2010|802
Acyclovir and Transmission of HIV-1 from Persons Infected with HIV-1 and HSV-2
|New England Journal of Medicine|2010|532